Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Krystal Biotech, Inc.Krystal Biotech to Present at 2026 Cantor Global Healthcare ConferenceKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day.
- ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT AUGUST 2026Zinzino group revenue increased with a total of 15 %, compared with the previous year. — The revenue in August for Zinzino's sales markets increased by 16 % and amounted to SEK 280.9 (242.5) million. Faun Pharma's external sales amounted to...
- Commure Ambient AI Achieves Class I Certification and MHRA RegistrationCommure Ambient AI is now available across the UK and Europe as CE-marked Class I medical device software, registered with the MHRA.
- ONWARD Medical Announces First Implant in New Clinical Feasibility Study Evaluating ARC-IM System to Restore Mobility After Spinal Cord InjuryEINDHOVEN, the Netherlands, Sept. 03, 2026 -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function, and independence, today announces the first implant in the EIGER clinical feasibility study evaluating the investigational ARC-IM® System for restoring mobility in people with subacute or chronic spinal cord injury (SCI).
- Eugene Pet Wellness Launches AI Platform Connecting Canine Genetic Data, Wellness Decisions and Ongoing Health InformationPatent-pending platform is designed to connect genetic insights, personalized guidance and evolving information about a dog's wellness needs
- Insilico MedicineInsilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value ChainInsilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in the HKEX Tech 100 Index, following the methodology enhancements to...
- Robbins Geller Rudman & Dowd LLPHIMS INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead the Hims & Hers Class Action LawsuitRobbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"), have until November 2, 2026 to seek appointment as...
- Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff DeadlineInvestors who lost money in CAPR after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung CancerRevolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral, RAS(ON) multi-selective inhibitor, in patients with previously treated advanced RAS mutant non-small cell lung cancer (NSCLC).
- BioRestorative Therapies Announces Reverse Stock SplitBioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company’s Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”). The Company was not required to obtain stockholder approval to effectuate the Reverse Stock Split under Nevada law. The Company filed a certificate of change with the Secretary of State of the State of Nevada, which is expected to become effective as of 4:30 P.M. Eastern Time on September 7, 2026. The Common Stock will begin trading on The Nasdaq Capital Market on a reverse split-adjusted basis at the start of trading on September 8, 2026, under the symbol “BRTX” and under a new CUSIP number, 090655705. The Company is effecting the Reverse Stock Split with the intention of regaining compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
- SEIU Local 2“Kevin Quinn: Hold Dexterra Accountable”: SEIU Local 2 holds rally outside TransLink officeSkyTrain cleaners employed by Dexterra Group have been sounding the alarm about serious safety concerns about their jobs over the last several months. TransLink has refused to meet the workers despite repeated requests. Now, WorkSafeBC inspections have backed up workers’ concerns, with reports outlining several health and safety violations that are still outstanding.
- CodoxoCodoxo Named a Winner in 2026 Fierce AI Innovation AwardsAI-powered Point Zero Payment Integrity recognized for helping health plans prevent payment errors before claims are created. — Codoxo, the leading provider of AI and generative AI-powered healthcare payment integrity solutions, today announced...